Key result
Therapeutic drug monitoring of antipsychotics lowers toxicity, improves compliance, and reduces costs.
Why the study?
Therapeutic drug monitoring of conventional and atypical antipsychotics offers clinical advantages but data are lacking for some drugs like risperidone and quetiapine.
Does therapeutic drug monitoring improve outcomes (cost savings, decreased toxicity, improved compliance) in patients taking antipsychotics?
Does therapeutic drug monitoring improve outcomes (cost savings, decreased toxicity, improved compliance) in patients taking antipsychotics?
Therapeutic drug monitoring is clinically useful for haloperidol, olanzapine, and clozapine, but data is lacking for risperidone and quetiapine.
No takes yet. Share an insight, caveat, or question.
May support TDM for haloperidol, olanzapine, and clozapine; leaves open confirmation via prospective trials before routine adoption.
Paul J. Perry (2025) reported a review. Therapeutic drug monitoring of antipsychotics was evaluated. Therapeutic drug monitoring of antipsychotics, particularly haloperidol, olanzapine, and clozapine, offers clinical advantages including cost savings, decreased toxicity, and improved compliance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: